TW200500079A - Compositions and methods for treating coronavirus infection and sars - Google Patents

Compositions and methods for treating coronavirus infection and sars

Info

Publication number
TW200500079A
TW200500079A TW093108408A TW93108408A TW200500079A TW 200500079 A TW200500079 A TW 200500079A TW 093108408 A TW093108408 A TW 093108408A TW 93108408 A TW93108408 A TW 93108408A TW 200500079 A TW200500079 A TW 200500079A
Authority
TW
Taiwan
Prior art keywords
coronavirus infection
reducing
methods
sars
present
Prior art date
Application number
TW093108408A
Other languages
English (en)
Inventor
Lawrence M Blatt
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of TW200500079A publication Critical patent/TW200500079A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
    • E04G19/00—Auxiliary treatment of forms, e.g. dismantling; Cleaning devices
    • E04G19/006—Cleaning devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Architecture (AREA)
  • Communicable Diseases (AREA)
  • Structural Engineering (AREA)
  • Civil Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093108408A 2003-04-01 2004-03-26 Compositions and methods for treating coronavirus infection and sars TW200500079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45978303P 2003-04-01 2003-04-01

Publications (1)

Publication Number Publication Date
TW200500079A true TW200500079A (en) 2005-01-01

Family

ID=33551338

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093108408A TW200500079A (en) 2003-04-01 2004-03-26 Compositions and methods for treating coronavirus infection and sars

Country Status (9)

Country Link
US (2) US20050002901A1 (zh)
EP (1) EP1651271A4 (zh)
JP (1) JP2006528679A (zh)
KR (1) KR20040088393A (zh)
CN (1) CN1533808A (zh)
CA (1) CA2520148A1 (zh)
SG (1) SG118236A1 (zh)
TW (1) TW200500079A (zh)
WO (1) WO2004110392A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
US20060280723A1 (en) * 2003-05-19 2006-12-14 Viragen, Inc Interferon for treating or preventing a coronaviral infection
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
CA2644670A1 (en) * 2006-03-08 2008-05-08 Hemispherx Biopharma Inc. Broad spectrum immune and antiviral gene modulation by oral interferon
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
IL295040A (en) * 2020-02-06 2022-09-01 Eiger Biopharmaceuticals Inc Treatment of corona virus infection using interferon has been studied
CN111346219B (zh) * 2020-02-21 2021-05-14 上海甘翼生物医药科技有限公司 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途
CN113425832A (zh) * 2020-03-23 2021-09-24 杭州先为达生物科技有限公司 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
US20230172885A1 (en) * 2020-05-13 2023-06-08 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
CN113813375B (zh) * 2020-06-19 2023-06-16 杭州星鳌生物科技有限公司 一种新型抗新冠病毒复合物的组成及其在防治冠状病毒感染疾病药物中的应用
US20220040265A1 (en) * 2020-08-07 2022-02-10 Peter G. Carroll Compositions and methods for preventing and/or inhibiting viral infection and spread
WO2022066798A1 (en) * 2020-09-24 2022-03-31 Southlake Pharmaceuticals, Inc. Interferon tau fc-fusion proteins and methods for treating coronavirus infections
US20220280450A1 (en) * 2021-03-05 2022-09-08 Philera New Zealand Ltd. Prevention and treatment of coronavirus and related respiratory infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
WO2004089983A2 (en) * 2003-04-08 2004-10-21 Coronovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
MXPA05011170A (es) * 2003-04-17 2005-12-14 Ares Trading Sa Interferon beta en el sindrome respiratorio agudo severo.
CN1449740A (zh) * 2003-05-14 2003-10-22 长春长生基因药业股份有限公司 具有杀灭病毒作用的α干扰素系列药物化妆品
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害

Also Published As

Publication number Publication date
JP2006528679A (ja) 2006-12-21
WO2004110392A3 (en) 2005-06-30
EP1651271A4 (en) 2006-11-08
KR20040088393A (ko) 2004-10-16
CN1533808A (zh) 2004-10-06
WO2004110392A2 (en) 2004-12-23
CA2520148A1 (en) 2004-12-23
US20090068142A1 (en) 2009-03-12
US20050002901A1 (en) 2005-01-06
EP1651271A2 (en) 2006-05-03
SG118236A1 (en) 2006-01-27

Similar Documents

Publication Publication Date Title
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
HK1059213A1 (en) Treatment of type 2 diabetes with inhibitors of dipetidyl peptidase iv
TW200630093A (en) Dose forms
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
RS20050344A (en) Treatment for hemorrhagic shock
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
IL183481A (en) Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
TW200621312A (en) Oral solid dosage forms containing a low dose of estradiol
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
WO2005089489A3 (en) Use of relaxin to increase arterial compliance
TW200503731A (en) Method of treatment
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
SE0203817D0 (sv) New composition
WO2004089283A3 (en) Compositions and methods for treating viral infections
MXPA04001230A (es) Uso de inhibidores de il-18 en desordenes de hipersensibilidad.
EP1390027A4 (en) COMPOSITION WITH DEMETHYLCANTHARIDINE IN COMBINATION WITH PLATINUM-CONTAINING ANTI-VITAL AGENTS AND THEIR USE